Affimed Announces Presentation of Preclinical Data on AFM13-targeted NK cells at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Rhea-AI Summary

Heidelberg, Germany, October 14, 2020 – Affimed N.V. (Nasdaq: AFMD) announced the presentation of preclinical data at the upcoming SITC Annual Meeting from its collaboration with MD Anderson Cancer Center and Washington University. The oral presentation is titled AFM13-targeted blood and cord-blood-derived memory-like NK cells as therapy for CD30+ malignancies and will occur on November 11, 2020. AFM13, a bispecific innate cell engager, targets CD30-positive tumor cells and is actively being tested in a registration-directed trial for relapsed/refractory peripheral T-cell lymphoma.

Positive

• Presentation of preclinical data at a reputable conference (SITC) can enhance visibility.
• AFM13 is in a registration-directed trial, indicating progress towards market approval.
• Collaboration with prestigious institutions like MD Anderson enhances credibility.

Negative

• None.

Heidelberg, Germany, October 14, 2020 – Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that preclinical data from its collaboration with The University of Texas MD Anderson Cancer Center and Washington University School of Medicine will be presented in an oral presentation at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held virtually on November 9-14, 2020.

Details of the oral presentation:

Title: AFM13-targeted blood and cord-blood-derived memory-like NK cells as therapy for CD30+ malignancies

Abstract ID: 349

Authors: Lucila Kerbauy, Nancy D. Marin, Mecit Kaplan, Pinaki Banerjee, Melissa Berrien-Elliott, Michelle Becker-Hapak, Rafet Basar, Mark Foster, Luciana Garcia Melo, Carly Neal, Ethan McClain, May Daher, Ana Karen Nunez Cortes, Francesca Wei Inng Lim, Mayela Carolina Mendt, Timothy Schappe, Li Li, Hila Shaim, Mayra Hernandez Sanabria, Pamela Wong, Enli Liu, Sonny Ang, Rong Cai, Vandana Nandivada, Vakul Mohanty, Yifei Shen, Natalia Baran, Natalie Fowlkes, Ken Chen, Luis Muniz-Feliciano, Joachim Koch, Martin Treder, Wolfgang Fischer, Oswaldo Keith Okamoto, Yago Nieto, Richard E. Champlin, Elizabeth J. Shpall, Todd A. Fehniger, Katayoun Rezvani

Date: November 11, 2020 during the concurrent session Innate Immunity: The Next Generation of Targets for Anti-Cancer Immunotherapy (3:45 – 5:15 pm EST).

Abstract Release: All abstracts will be available on November 09, 2020 at 8:00 am EST.

For more details about the SITC Virtual Annual Meeting please visit:  www.sitcancer.org/2020/home.

About AFM13

AFM13 is a first-in-class CD30/CD16A ROCK^®-derived bispecific innate cell engager (ICE^®) that induces specific and selective killing of CD30-positive tumor cells by engaging and activating natural killer (NK) cells and macrophages, thereby leveraging the power of the innate immune system. AFM13 is Affimed’s most advanced ICE^® clinical program, and it is currently being evaluated as a monotherapy in a registration-directed trial in patients with relapsed/refractory peripheral T-cell lymphoma (REDIRECT). The study is actively recruiting and can be found at www.clinicaltrials.gov using the identifier NCT04101331.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer. Affimed’s fit-for-purpose ROCK^® platform allows innate cell engagers to be designed for specific patient populations. The company is developing single and combination therapies to treat hematologic and solid tumors. The company is currently enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T cell lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. For more information, please visit www.affimed.com.

Affimed Investor Contact

Alex Fudukidis
Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: (917) 436-8102

FAQ

What is the purpose of the AFM13 study presented by Affimed?

The AFM13 study aims to evaluate the safety and efficacy of targeting CD30-positive tumor cells through the use of memory-like NK cells.

When will the AFM13 preclinical data be presented?

The AFM13 preclinical data will be presented on November 11, 2020, during the SITC Annual Meeting.

What is the significance of the collaboration between Affimed and MD Anderson?

The collaboration with MD Anderson and Washington University enhances the credibility and scientific rigor of the AFM13 study.

What are the next steps for Affimed following the SITC presentation?

Following the presentation, Affimed will continue to focus on the ongoing registration-directed trial for AFM13 in relapsed/refractory peripheral T-cell lymphoma.

What type of therapy does AFM13 represent?

AFM13 is a first-in-class bispecific innate cell engager (ICE) designed to activate natural killer cells against CD30-positive malignancies.